An increased expression of CTGF was reported in infarcted and non-infarcted cardiac tissues [91]–[92], indicating CTGF as an attractive therapeutic target to treat fibrotic diseases and suggesting the use of its plasma levels as a biomarker for heart failure [21]. This evidence concerns the gene CCN2 and heart failure.